An Ohio man was found guilty of seven crimes: one count each of conspiracy to commit armed pharmacy robbery and conspiracy to possess with the intent to distribute controlled substances, three counts of armed pharmacy robbery, and two counts of pharmacy robbery.
Jamea, 26, formerly of Columbus, Ohio, was tried before United States Senior District Judge Arthur J. Schwab in Pittsburgh.
Evidence introduced during the four-day trial, through 19 witnesses, established that the defendant participated in a conspiracy to rob pharmacies of Schedule II controlled substances—that is, highly addictive opioids and stimulants—between September 2018 and July 2019.
Read: Michigan Mom And Dad Charged With Starving Their 2-Year-Old To Death
This conspiracy included the robberies of pharmacies in Beaver, Bridgeville, Edinboro, Erie, and the Oakland area of Pittsburgh, Pennsylvania.
During three of the robberies, Jamea and his co-conspirators brandished a firearm to threaten the lives of pharmacists and pharmacy technicians and to intimidate them into opening the locked safes where the controlled substances were kept. Evidence also established that the defendant went on to distribute these stolen narcotics in the Columbus, Ohio, area.
Judge Schwab scheduled sentencing for July 31, 2024. The maximum penalty for the most serious offense of conviction is 25 years in prison, a fine of up to $250,000, or both.
Read: 1 Dead, 1 In Critical Condition After Overnight Shooting In Tampa
Under the federal Sentencing Guidelines, the actual sentence imposed is based on the offenses’ seriousness and the defendant’s prior criminal history.
Jamea is currently serving a prison sentence of more than 40 years following his earlier conviction in Ohio state court for multiple counts of felonious assault with a firearm. He remains in custody pending his sentencing in the Western District of Pennsylvania.
Help support the Tampa Free Press by making any small donation by clicking here.
Android Users, Click To Download The Tampa Free Press App And Never Miss A Story. Follow Us On Facebook and Twitter. Sign up for our free newsletter.